The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stern, B. V.
Right arrow Articles by Tary-Lehmann, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stern, B. V.
Right arrow Articles by Tary-Lehmann, M.
The Journal of Immunology, 2002, 168: 6099-6105.
Copyright © 2002 by The American Association of Immunologists

Vaccination with Tumor Peptide in CpG Adjuvant Protects Via IFN-{gamma}-Dependent CD4 Cell Immunity1

Britta V. Stern*,{dagger}, Bernhard O. Boehm{dagger} and Magdalena Tary-Lehmann2,*

* Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106; and {dagger} Section of Endocrinology, University Hospitals, Ulm, Germany

The low frequency of tumor Ag-specific T cells in vivo has made it challenging to directly measure their clonal sizes and cytokine signatures. We used a new generation ELISPOT approach to study the constitutive immunogenicity of the RMA tumor in syngeneic B6 mice and adjuvant-guided immunity against an MHC class II-restricted RMA peptide, H11.1. The RMA tumor was found to activate cells of the innate immune system and to induce a type 1 polarized, RMA-specific CD4 and CD8 T cell response. With clonal sizes ~10/106, the magnitude of this constitutively induced immune response did not suffice to control the tumor cell growth. In contrast, immunization with H11.1 peptide, using an immunostimulatory CpG oligonucleotide or CFA as adjuvant, engaged ~25- or ~10-fold higher clonal sizes of type 1 polarized CD4 cells, respectively. Therefore, the CpG oligonucleotide functioned as a stronger type 1 adjuvant and, unlike CFA, elicited protective immunity. The protection was IFN-{gamma} dependent, as it was not inducible in IFN-{gamma} knockout mice. Therefore, CpG adjuvant-guided induction of type 1 immunity against tumor Ags might be a promising subunit vaccination approach.




This article has been cited by other articles:


Home page
J. Immunol.Home page
J. T. Tigno-Aranjuez, R. Jaini, V. K. Tuohy, P. V. Lehmann, and M. Tary-Lehmann
Encephalitogenicity of Complete Freund's Adjuvant Relative to CpG Is Linked to Induction of Th17 Cells
J. Immunol., November 1, 2009; 183(9): 5654 - 5661.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Vasir, Z. Wu, K. Crawford, J. Rosenblatt, C. Zarwan, A. Bissonnette, D. Kufe, and D. Avigan
Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells
J. Immunol., July 1, 2008; 181(1): 808 - 821.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Atanackovic, N. K. Altorki, Y. Cao, E. Ritter, C. A. Ferrara, G. Ritter, E. W. Hoffman, C. Bokemeyer, L. J. Old, and S. Gnjatic
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming
PNAS, February 5, 2008; 105(5): 1650 - 1655.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Fujii, J. D. Trudeau, D. T. Teachey, J. D. Fish, S. A. Grupp, K. R. Schultz, and G. S. D. Reid
In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides
Blood, March 1, 2007; 109(5): 2008 - 2013.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. F. Eisenbeis, G. B. Lesinski, M. Anghelina, R. Parihar, D. Valentino, J. Liu, P. Nadella, P. Sundaram, D. C. Young, M. Sznol, et al.
Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12
J. Clin. Oncol., December 1, 2005; 23(34): 8835 - 8844.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Gregoire, A. S. Bergot, C. Feraudet, C. Carnaud, P. Aucouturier, and M. B. Rosset
The Murine B Cell Repertoire Is Severely Selected against Endogenous Cellular Prion Protein
J. Immunol., November 15, 2005; 175(10): 6443 - 6449.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. R. Weihrauch, S. Ansen, E. Jurkiewicz, C. Geisen, Z. Xia, K. S. Anderson, E. Gracien, M. Schmidt, B. Wittig, V. Diehl, et al.
Phase I/II Combined Chemoimmunotherapy with Carcinoembryonic Antigen-Derived HLA-A2-Restricted CAP-1 Peptide and Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Primary Metastatic Colorectal Cancer
Clin. Cancer Res., August 15, 2005; 11(16): 5993 - 6001.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. Oumouna, J. W. Mapletoft, B. C. Karvonen, L. A. Babiuk, and S. van Drunen Littel-van den Hurk
Formulation with CpG Oligodeoxynucleotides Prevents Induction of Pulmonary Immunopathology following Priming with Formalin-Inactivated or Commercial Killed Bovine Respiratory Syncytial Virus Vaccine
J. Virol., February 15, 2005; 79(4): 2024 - 2032.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. J. Kemp, J. M. Moore, and T. S. Griffith
Human B Cells Express Functional TRAIL/Apo-2 Ligand after CpG-Containing Oligodeoxynucleotide Stimulation
J. Immunol., July 15, 2004; 173(2): 892 - 899.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. B. Rosset, C. Ballerini, S. Gregoire, P. Metharom, C. Carnaud, and P. Aucouturier
Breaking Immune Tolerance to the Prion Protein Using Prion Protein Peptides Plus Oligodeoxynucleotide-CpG in Mice
J. Immunol., May 1, 2004; 172(9): 5168 - 5174.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Atanackovic, N. K. Altorki, E. Stockert, B. Williamson, A. A. Jungbluth, E. Ritter, D. Santiago, C. A. Ferrara, M. Matsuo, A. Selvakumar, et al.
Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients
J. Immunol., March 1, 2004; 172(5): 3289 - 3296.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
Y.-F. Chen, C.-W. Lin, Y.-P. Tsao, and S.-L. Chen
Cytotoxic-T-Lymphocyte Human Papillomavirus Type 16 E5 Peptide with CpG-Oligodeoxynucleotide Can Eliminate Tumor Growth in C57BL/6 Mice
J. Virol., February 1, 2004; 78(3): 1333 - 1343.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. S. Lonsdorf, H. Kuekrek, B. V. Stern, B. O. Boehm, P. V. Lehmann, and M. Tary-Lehmann
Intratumor CpG-Oligodeoxynucleotide Injection Induces Protective Antitumor T Cell Immunity
J. Immunol., October 15, 2003; 171(8): 3941 - 3946.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Flynn and B. Stockinger
Tumor and CD4 T-cell interactions: tumor escape as result of reciprocal inactivation
Blood, June 1, 2003; 101(11): 4472 - 4478.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Woodberry, J. Gardner, S. L. Elliott, S. Leyrer, D. M. Purdie, P. Chaplin, and A. Suhrbier
Prime Boost Vaccination Strategies: CD8 T Cell Numbers, Protection, and Th1 Bias
J. Immunol., March 1, 2003; 170(5): 2599 - 2604.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. M. Addo, X. G. Yu, A. Rathod, D. Cohen, R. L. Eldridge, D. Strick, M. N. Johnston, C. Corcoran, A. G. Wurcel, C. A. Fitzpatrick, et al.
Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load
J. Virol., February 1, 2003; 77(3): 2081 - 2092.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.